Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Pulmozyme Generic Name & Formulations
Legal Class
Rx
General Description
Dornase alfa (recombinant human DNase) 1mg/mL; soln for inh; preservative-free.
How Supplied
Ampules (2.5mL)—30
Manufacturer
Generic Availability
NO
Mechanism of Action
Pulmozyme is recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, it hydrolyzes the DNA in sputum of cystic fibrosis patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection.
Pulmozyme Indications
Indications
Management of cystic fibrosis in conjunction with standard therapies to improve pulmonary function.
Pulmozyme Dosage and Administration
Adults and Children
<3months: not recommended. Use appropriate nebulizer (jet or vibrating mesh). Do not dilute. >5yrs: 2.5mg once daily via nebulization; may increase to 2.5mg twice daily (see full labeling).
Pulmozyme Contraindications
Not Applicable
Pulmozyme Boxed Warnings
Not Applicable
Pulmozyme Warnings/Precautions
Warnings/Precautions
For patients <5yrs of age, use only if there is a potential for benefit in pulmonary function or in risk of respiratory tract infection. Use only with recommended nebulizers. Pregnancy. Nursing mothers.
Pulmozyme Pharmacokinetics
Elimination
Half-life: 3–4 hours.
Pulmozyme Interactions
Interactions
Do not mix with other drugs in nebulizer.
Pulmozyme Adverse Reactions
Adverse Reactions
Pharyngitis, voice alteration, laryngitis, rash, chest pain, conjunctivitis.
Pulmozyme Clinical Trials
See Literature
Pulmozyme Note
Not Applicable
Pulmozyme Patient Counseling
See Literature
